Rein Therapeutics Inc. Ordinary Shares RNTX 深 滬
等待開盤 07-19 09:30:00 美东时间
1.42
+0.020
+1.43%
華盛通- 最 高1.46
- 今 開1.42
- 成交量 1.04万股
- 最 低 1.37
- 昨 收 1.40
- 總市值 3145.83万
- 52周最高 4.40
- 市盈率 靜 --
- 換手率 0.05%
- 52周最低 1.33
- 委 比 -88.47%
- 總股本 2215.37万
- 歷史最高 309.60
- 量 比 0.33
- 振 幅 6.43%
- 歷史最低 1.01
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Rein Therapeutics Adjourns 2025 Annual Meeting
Rein Therapeutics ( ($RNTX) ) has issued an update. On June 24, 2025, Rein Ther...
06-25 04:41
Rein Therapeutics Announces Adjournment of Annual Meeting of Stockholders
Meeting adjourned to Wednesday, July 23, 2025 at 9:00 a.m. Eastern Time AUSTIN, Texas, June 24, 2025 /PRNewswire/ -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company ad...
06-24 22:11
晶泰科技(02228)与美国生物制药传奇Gregory Verdine旗下公司达成战略合作 联手打造最强AI制药平台
6月23日，量子物理、AI与机器人药物及新材料研发平台晶泰科技(02228)宣布与美国化学生物学泰斗Gregory Verdine创立的DoveTree LL...
06-24 11:18
Rein Therapeutics Pauses U.S. Enrollment for RENEW Trial
Rein Therapeutics ( ($RNTX) ) has shared an announcement. On June 10, 2025, Rei...
06-13 04:54
Rein Therapeutics Doses First Patient in Phase 2 Trial for IPF Drug LTI-03
Rein Therapeutics ("Rein") (NASDAQ:RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications,
05-27 19:05
Rein Therapeutics Q1 EPS $(0.25) Misses $(0.24) Estimate
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 70.93 percent increase over losses of $(0.86) per share
05-16 04:21
Rein Therapeutics Q4 EPS $(1.89) Down From $(1.54) YoY
Rein Therapeutics (NASDAQ:RNTX) reported quarterly losses of $(1.89) per share. This is a 22.73 percent decrease over losses of $(1.54) per share from the same period last year.
04-08 04:21
Rein Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Rein advanced the clinical development of its lead asset, LTI-03, and aims to initiate a Phase 2 trial for the treatment of idiopathic pulmonary fibrosis (IPF) in the first half of 2025 Posi...
04-08 04:17
